As an original signatory to the ATMI Investor Statement, ICCR members welcomed the new report. Of the seven areas covered by the study, the results indicate that positive strides are being made by the pharma industry as a whole in terms of developing and scaling innovations to improve access and affordability, however, the study indicates that progress has been weaker in two key areas: Public Policy & Market Influence and Patents & Licensing.